Susquehanna International Group
KALV

Susquehanna International Group’s KalVista Pharmaceuticals KALV Stock Holding History

Susquehanna International Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,700
Closed -$477K – 13990
2026
Q1 		$477K Buy
+23,700
New +$382K ﹤0.01% 9799
2024
Q4 		– Sell
-12,300
Closed -$142K – 12737
2024
Q3 		$142K Sell
12,300
-4,300
-26% -$54.1K ﹤0.01% 10791
2024
Q2 		$196K Sell
16,600
-25,300
-60% -$295K ﹤0.01% 10382
2024
Q1 		$497K Sell
41,900
-36,000
-46% -$480K ﹤0.01% 8525
2023
Q4 		$954K Buy
77,900
+24,200
+45% +$220K ﹤0.01% 7102
2023
Q3 		$517K Sell
53,700
-52,800
-50% -$539K ﹤0.01% 8150
2023
Q2 		$959K Buy
+106,500
New +$982K ﹤0.01% 6775
2022
Q1 		– Sell
-10,400
Closed -$138K – 13513
2021
Q4 		$138K Sell
10,400
-89,500
-90% -$1.42M ﹤0.01% 11886
2021
Q3 		$1.74M Buy
99,900
+6,800
+7% +$138K ﹤0.01% 6147
2021
Q2 		$2.23M Sell
93,100
-37,500
-29% -$981K ﹤0.01% 5666
2021
Q1 		$3.35M Sell
130,600
-23,100
-15% -$607K ﹤0.01% 4721
2020
Q4 		$2.92M Buy
+153,700
New +$2.64M ﹤0.01% 4354

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's KALV Position: Q2 2026 in Review

Susquehanna International Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 46,760 shares — an estimated $941K sold.

Susquehanna International Group first reported a position in KALV in Q2 2016 and held it in 24 quarters. The position peaked at $4.79M in Q3 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Susquehanna International Group reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Susquehanna International Group sold 46,760 KalVista Pharmaceuticals shares in Q2 2026, an estimated $941K.
  • Susquehanna International Group first reported a position in KalVista Pharmaceuticals in Q2 2016 and held it in 24 quarters.
  • Susquehanna International Group's KalVista Pharmaceuticals position peaked at $4.79M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.